Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. (Q46243261)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

Markus Peck-Radosavljevic

10 March 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

Katharina Grabmeier-Pfistershammer

10 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

L Kosi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

B A Payer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

R Strassl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

A Rieger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

15 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

801-810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology of viral hepatitis and HIV co-infection

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Telbivudine has activity against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01601.X

10.1111/J.1365-2893.2012.01601.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23043387%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference